Valuation: Adimmune Corporation

Market Cap 6.24B 189M 172M 159M 144M 271M 17.52B 285M 1.93B 768M 9.57B 710M 695M 30.04B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.24B 189M 172M 159M 144M 271M 17.52B 285M 1.93B 768M 9.57B 710M 695M 30.04B EV / Sales 2026 *
4.12x
EV / Sales 2027 * 3.72x
Free-Float
76.85%
Yield 2026 *
-
Yield 2027 * -
1 day-6.62%
1 week-11.38%
Current month-13.95%
1 month-16.85%
3 months-14.20%
6 months-14.70%
Current year-21.90%
1 week 14.8
Extreme 14.80000000
17
1 month 14.8
Extreme 14.80000000
18.05
Current year 14.8
Extreme 14.80000000
21.5
1 year 14.8
Extreme 14.80000000
21.5
3 years 14.8
Extreme 14.80000000
36.6
5 years 14.8
Extreme 14.80000000
48.85
10 years 14.8
Extreme 14.80000000
79.8
Manager TitleAgeSince
Chief Executive Officer - 19/06/2019
Director of Finance/CFO - 31/12/2020
Chief Tech/Sci/R&D Officer - 25/01/2022
Director TitleAgeSince
Director/Board Member - 19/06/2019
Director/Board Member - 14/08/2011
Director/Board Member - 28/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-6.62%-11.38%-27.09%-55.22% 202M
+0.05%-6.27%+29.68%+126.40% 1,204B
+1.64%-5.28%+33.29%+80.55% 643B
+1.76%-2.23%+25.72%+108.56% 501B
-0.60%-1.95%+27.26%+67.32% 378B
+1.25%-9.01%+41.56%+30.93% 327B
+0.41%-4.70%+27.23%+51.59% 285B
+0.81%-4.08%-1.74%+32.71% 270B
+0.45%-5.70%+30.67%+65.49% 237B
+1.01%+0.29%+34.87%+121.80% 207B
Average -0.01%-4.91%+22.14%+63.01% 405B
Weighted average by Cap. +0.68%-4.71%+28.55%+88.37%

Financials

2026 *2027 *
Net sales 1.52B 45.96M 41.86M 38.57M 35.08M 65.82M 4.26B 69.17M 469M 187M 2.32B 172M 169M 7.29B 1.68B 50.87M 46.33M 42.69M 38.84M 72.86M 4.71B 76.57M 520M 207M 2.57B 191M 187M 8.07B
Net income - -
Net Debt - -
Projected Income Statement - Annual - Adimmune Corporation
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
19/11/26 NT$14.80 -6.62% 1,618,310
19/11/26 NT$15.85 -1.86% 1,603,109
18/11/26 NT$16.15 -0.62% 534,848
17/11/26 NT$16.25 -0.61% 629,985
16/11/26 NT$16.35 -2.68% 726,652
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Adimmune Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
14.80TWD
Average target price
21.00TWD
Spread / Average Target
+41.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adimmune Corporation
  1. Stock Market
  2. Stocks
  3. 4142 Stock